Table 2. Outcomes after unrelated HCT... | American Society of Hematology

Table 2.

Outcomes after unrelated HCT (grouped by diagnoses)

UPN	Disease + status	% Donor CD3 cells		Graft rejection	GVHD		Survival, d	Summary of outcome as of 09/01/2001
UPN	Disease + status	Day 28	Day 56	Graft rejection	Acute (grade)	Chronic	Survival, d	Summary of outcome as of 09/01/2001
SPN2292	ALL/CR2	90	100	No	II	Ext	211^†	CR, cGVHD, pneumonia/MOF
UL755	ALL/CR2	83	88	No	IV	No	109^†	CR, aGVHD, infection
SPN2292	AML/CR1	100	65	No	II	Lim	> 549	CR, alive
UL676	AML/CR2	85	100	No	II	Lim	156^†	CR, sudden death
UL652	AML/CR3	100	100	No	I	Lim	> 844	CR, alive
FH15303	AML/CR3	90	90	No	III	No	144^†	CR, GI bleed
UL637	AML/CR3	100	100	No	IV	No	170^†	CR, aGVHD
FH16411	AML/CR4	100	100	No	II	Ext	401^†	CR, CNS infection/sev. GvHD
UL665	AML/PR2	75	80	No	II	Lim	> 789	CR, alive
UL668	AML/prog	96	99	No	II	Ext	624^†	CR, infection (urosepsis)
UL680	AML/prog	95	99	No	II	Lim	218^†	Relapse
UL692	AML/rel1	100	100	No	II	Lim	> 705	CR, alive
UL656	CLL/PR	100	100	No	I	Lim	> 817	CR, alive
UL698	CLL/PR	88	86	No	II	Ext	482^†	CR, suicide, chronic GVHD
FH16078	CLL/rel	99	99	No	II	Ext	> 480	CR, alive
UL597	CML/AP	75	80	No	III	No	122^†	Progression
UL641	CML/AP	70	NA	No	II	No	46^†	NE, TTP
UL670	CML/AP	0	NA	Yes	NA	NA	172^†	Relapse
UL672	CML/CP	75	85	No	III	Lim	546^†	CR, cGVHD
UL695	CML/AP	100	100	No	IV	Lim	> 698	CR, alive
UL709	CML/CP	80	70	No	IV	Lim	312^†	CR, cGVHD
UL725	CML/CP	0	NA	Yes	NA	NA	203^†	NE, infection 2nd BMT
UL730	CML/CP	90	93	No	IV	No	61^†	NE, aGVHD
UL735	CML/CP	95	100	No	I	No	377^†	Relapse
UL754	CML/CP2	90	100	No	I	No	> 492	CR, alive
UC001	CML/AP	NA	90	No	II	Ext	241^†	Progression
UC002	CML/BC	NA	NA	No	NA	NA	20^†	Progression
FH15764	Hodgkin disease/rel	90	99	No	III	Ext	> 581	Relapse, alive
UL701	NHL/refr B cell	100^*	NA	No	IV	NA	13^†	CR, VOD, ARDS
SPN2219	NHL/rel diff. large cell	100	100	No	0	Ext	> 584	CR, alive
FH13715	NHL/rel MCL	10	40	No	0	No	> 575	Relapse, alive
FH16020	NHL/rel MCL	59	43	No	II	Ext	> 548	CR, alive
UL744	NHL/rel high-grade T cell	0	NA	No	0	No	40^†	Progression
FH15780	NHL/PR MCL	99	100	No	II	Ext	> 451	CR, alive
FH17028	WM/refr	81	90	No	II	Lim	293^†	Stable disease, infection^‡
FH15390	MDS/RA	60	0	Yes	II	NA	210^†	Relapse, infection 2nd BMT
SPN2219	MDS/CMML	65	30	No	0	No	178^†	Relapse
SPN2264	MDS/RAEB-T	NA	NA	No	0	NA	18^†	NE, MOF, sepsis
UL760	MDS/CMML	100	100	No	I	No	> 474	CR, alive
FH11799	MDS/RAEB	NA	NA	No	II	NA	21^†	NE, pneumonia
FH15608	MDS/AML/CR	0	0	Yes	NA	NA	215^†	Relapse
FH16391	MDS/AML refr	0	NA	Yes	NA	NA	153^†	Relapse
FH15595	MDS/MPS	43	65	No	0	Ext	> 470	Stable disease, alive
UL664	MM/rel	100	100	No	I	Lim	602^†	Relapse
UL714	MM/rel	90	90	No	0	No	> 641	Progression, alive
UL733	MM/rel	100	100	No	II	Lim	228^†	Progression
UL747	MM/PR	98	100	No	II	Ext	> 515	Relapse, alive
UL753	MM/PR	0	NA	Yes	NA	NA	166^†	Stable disease, inf. 2nd BMT
FH15711	MM/refr	90	NA	No	II	NA	89^†	Progression, inf. 2nd BMT
UL765	MM/PR	100	100	No	IV	NA	59^†	NE, aGVHD, bleeding
FH14886	MM/refr	99	100	No	II	Ext	271^†	Progressive disease
UL703	PNH	85	90	No	II	Lim	> 683	CR, alive

UPN	Disease + status	% Donor CD3 cells		Graft rejection	GVHD		Survival, d	Summary of outcome as of 09/01/2001
UPN	Disease + status	Day 28	Day 56	Graft rejection	Acute (grade)	Chronic	Survival, d	Summary of outcome as of 09/01/2001
SPN2292	ALL/CR2	90	100	No	II	Ext	211^†	CR, cGVHD, pneumonia/MOF
UL755	ALL/CR2	83	88	No	IV	No	109^†	CR, aGVHD, infection
SPN2292	AML/CR1	100	65	No	II	Lim	> 549	CR, alive
UL676	AML/CR2	85	100	No	II	Lim	156^†	CR, sudden death
UL652	AML/CR3	100	100	No	I	Lim	> 844	CR, alive
FH15303	AML/CR3	90	90	No	III	No	144^†	CR, GI bleed
UL637	AML/CR3	100	100	No	IV	No	170^†	CR, aGVHD
FH16411	AML/CR4	100	100	No	II	Ext	401^†	CR, CNS infection/sev. GvHD
UL665	AML/PR2	75	80	No	II	Lim	> 789	CR, alive
UL668	AML/prog	96	99	No	II	Ext	624^†	CR, infection (urosepsis)
UL680	AML/prog	95	99	No	II	Lim	218^†	Relapse
UL692	AML/rel1	100	100	No	II	Lim	> 705	CR, alive
UL656	CLL/PR	100	100	No	I	Lim	> 817	CR, alive
UL698	CLL/PR	88	86	No	II	Ext	482^†	CR, suicide, chronic GVHD
FH16078	CLL/rel	99	99	No	II	Ext	> 480	CR, alive
UL597	CML/AP	75	80	No	III	No	122^†	Progression
UL641	CML/AP	70	NA	No	II	No	46^†	NE, TTP
UL670	CML/AP	0	NA	Yes	NA	NA	172^†	Relapse
UL672	CML/CP	75	85	No	III	Lim	546^†	CR, cGVHD
UL695	CML/AP	100	100	No	IV	Lim	> 698	CR, alive
UL709	CML/CP	80	70	No	IV	Lim	312^†	CR, cGVHD
UL725	CML/CP	0	NA	Yes	NA	NA	203^†	NE, infection 2nd BMT
UL730	CML/CP	90	93	No	IV	No	61^†	NE, aGVHD
UL735	CML/CP	95	100	No	I	No	377^†	Relapse
UL754	CML/CP2	90	100	No	I	No	> 492	CR, alive
UC001	CML/AP	NA	90	No	II	Ext	241^†	Progression
UC002	CML/BC	NA	NA	No	NA	NA	20^†	Progression
FH15764	Hodgkin disease/rel	90	99	No	III	Ext	> 581	Relapse, alive
UL701	NHL/refr B cell	100^*	NA	No	IV	NA	13^†	CR, VOD, ARDS
SPN2219	NHL/rel diff. large cell	100	100	No	0	Ext	> 584	CR, alive
FH13715	NHL/rel MCL	10	40	No	0	No	> 575	Relapse, alive
FH16020	NHL/rel MCL	59	43	No	II	Ext	> 548	CR, alive
UL744	NHL/rel high-grade T cell	0	NA	No	0	No	40^†	Progression
FH15780	NHL/PR MCL	99	100	No	II	Ext	> 451	CR, alive
FH17028	WM/refr	81	90	No	II	Lim	293^†	Stable disease, infection^‡
FH15390	MDS/RA	60	0	Yes	II	NA	210^†	Relapse, infection 2nd BMT
SPN2219	MDS/CMML	65	30	No	0	No	178^†	Relapse
SPN2264	MDS/RAEB-T	NA	NA	No	0	NA	18^†	NE, MOF, sepsis
UL760	MDS/CMML	100	100	No	I	No	> 474	CR, alive
FH11799	MDS/RAEB	NA	NA	No	II	NA	21^†	NE, pneumonia
FH15608	MDS/AML/CR	0	0	Yes	NA	NA	215^†	Relapse
FH16391	MDS/AML refr	0	NA	Yes	NA	NA	153^†	Relapse
FH15595	MDS/MPS	43	65	No	0	Ext	> 470	Stable disease, alive
UL664	MM/rel	100	100	No	I	Lim	602^†	Relapse
UL714	MM/rel	90	90	No	0	No	> 641	Progression, alive
UL733	MM/rel	100	100	No	II	Lim	228^†	Progression
UL747	MM/PR	98	100	No	II	Ext	> 515	Relapse, alive
UL753	MM/PR	0	NA	Yes	NA	NA	166^†	Stable disease, inf. 2nd BMT
FH15711	MM/refr	90	NA	No	II	NA	89^†	Progression, inf. 2nd BMT
UL765	MM/PR	100	100	No	IV	NA	59^†	NE, aGVHD, bleeding
FH14886	MM/refr	99	100	No	II	Ext	271^†	Progressive disease
UL703	PNH	85	90	No	II	Lim	> 683	CR, alive

Day 12.

†

Death.

‡

Infection after induction therapy for secondary AML.

NA indicates not available.

View Large

This Feature Is Available To Subscribers Only